On the other hand, breast cancer cells with PTEN deficiency were found to be resistant to PI3K inhibitors (Tanaka et al., 2011), PI3K/mTOR inhibitors (Brachmann et al., 2009) or mTOR inhibitors (Weigelt et al., 2011) whereas some of the PTEN-deficient breast cancer cell lines were sensitive to inhibitors of the PI3K pathway (She et al., 2008; Lehmann et al., 2011; Sanchez et al., 2011; Tanaka et al., 2011). This evidence concerns the gene MTOR and breast cancer.